Another SGLT2 inhibitor, ertugliflozin, was approved for glycemic control in adults with type 2 diabetes. The once-daily, single therapy oral agent was approved as an adjunct to diet and exercise and will be available in two doses, 5mg and 15mg tablets. The approval also encompasses two ertugliflozin combination treatments, including combination sitagliptin, as well as combination metformin therapy.